Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Addrenex reports positive results from second Phase III ADHD trial
The current study of 200 children with attention deficit hyperactivity disorder (ADHD) is the second Phase III trial in a year to investigate the safety and efficacy of
The current study of 200 children with attention deficit hyperactivity disorder (ADHD) is the second Phase III trial in a year to investigate the safety and efficacy of
Under the terms of the agreement, Sucampo will hold the exclusive rights to commercialize Rescula in the US and Canada for the treatment of glaucoma and ocular hypertension.
Steven Ritter, vice president of intellectual property and contracts at Idera, said: “We continue to strengthen Idera’s patent portfolio covering compounds targeted to Toll-like receptors. The claims of
Revenues in the first quarter of 2009 were $9.1 million, up from $7.1 million in the first quarter of 2008. Revenues increased primarily as a result of the
The company has reported basic earnings per share of $0.87 for the first quarter of 2009, a decrease of 15%, compared to $1.02 for the first quarter of
Corventis’s inaugural product, the Avivo mobile patient management system, has received the FDA’s clearance and is now commercially available for use by clinicians within and outside the US.
The study will be conducted by the South African Tuberculosis Vaccine Initiative (SATVI) of University of Cape Town in the Western Cape Region from its study site 100km
According to Bolton Medical, the new delivery system features: hydrophilic coating on outer sheath and tip for easier introduction and advancement through the aorta; longer 60cm braided outer
Piper Jaffray & Co was the sole manager of the offering. The company intends to use the net proceeds to support commercialization, sales, marketing and general administrative activities,
The strategic acquisition allows NuVasive the potential to accelerate its entry into the growing mechanical cervical disc replacement market, said NuVasive. The initial payment for purchase of Cervitech